IP Library › Granted Patent US 7,994,191

Granted Patent B2

US 7,994,191 · App. 12/629,382 · Granted Aug 9, 2011

Heterocyclic cyclopamine analogs and methods of use thereof

Assignee: Infinity Discovery, Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,994,191
App. No.: 12/629,382
Granted: Aug 9, 2011
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer.

Claims (117)

1. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 1a or 1b:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 1 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, —SR 20 , —OR 20 , —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , —[(W)—C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , —[(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)—C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 ;

each of R 2 , R 6 and R 9 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, nitrile, alkoxyl, aryloxy, acyloxy, halide, hydroxyl, amino, alkylamino, arylamino, acylamino, aralkylamino, alkylseleno, aralkylseleno, arylseleno, alkylthio, aralkylthio, or arylthio;

R 3 is H; or R 2 and R 3 taken together form a bond;

each of R 4 and R 5 independently is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, nitrile, aralkyl, alkoxyl, aryloxy, acyloxy, halide, sulfhydryl, alkylthio, arylthio, aralkylthio, hydroxyl, amino, alkylamino, arylamino, acylamino, aralkylamino, heteroaryl, or heteroaralkyl; or R 4 and R 5 taken together form ═O, ═S, ═N(R 20 ), ═N—OR 20 , or ═N(N(R 20 ) 2 );

each of R 7 and R 8 independently is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, or aralkyl; or R 6 and R 7 taken together form a bond; or R 8 and R 9 taken together form a bond;

each of R 10 and R 11 independently is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, or aralkyl; or R 9 and R 10 taken together form a bond; or R 10 and R 11 taken together form a bond;

R 20 independently for each occurrence is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, or —[C(R) 2 ] q —R 21 ; or any two occurrences of R 20 can be taken together to form a 4-8 membered optionally substituted ring which contains 0-3 heteroatoms selected from N, O, S, and P;

R 21 independently for each occurrence is H, cycloalkyl, aryl, heteroaryl, heterocyclyl; alkoxyl, aryloxy, acyloxy, halide, sulfhydryl, alkylthio, arylthio, aralkylthio, hydroxyl, amino, acylamino, amido, or carbonyl-containing group;

R 22 independently for each occurrence is H, halide, ester, amide, or nitrile;

R 23 independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloalkyl, halide, nitro, nitrile, ═O, —SR 20 , —OR 20 , —N(R 20 )(R 20 ), —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —N(R 20 )C(O)R 20 , —N(R 20 )C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —N(R 20 )S(O) 2 R 20 , or —[C(R) 2 ] q —R 21 ;

R 24 independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloalkyl, halide, nitro, nitrile, —SR 20 , —OR 20 , —N(R 20 )(R 20 ), —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —N(R 20 )C(O)R 20 , —N(R 20 )C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —N(R 20 )S(O) 2 R 20 , or —[C(R 20 ) 2 ] q —R 21 ;

p is 0, 1, 2, 3, 4, 5, or 6;

q is 0, 1, 2, 3, 4, 5, or 6;

R independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl;

-T 1 -T 2 -T 3 - is Y—B-A, B—Y-A, or A-B—Y;

each of A and B independently is N, S or C(R 23 );

W is a diradical;

X is a bond or —C(R 22 ) 2 —;

Y is —O—, —S—, or —N(R 24 )—;

and each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, whether alone or part of another group, is optionally substituted;

wherein said cancer is selected from the group consisting of acute lymphocytic leukemia, basal cell carcinoma, bile duct cancer, glioma, breast cancer, chondrosarcoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatocellular cancer, lung cancer, medulloblastoma, melanoma, multiple myeloma, neuroectodermal tumors, non-Hodgkin's type lymphoma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, prostate cancer, testicular cancer, and sarcoma.

2. The method according to claim 1 , wherein R 1 is H, alkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, —OR 20 , —C(O)R 20 , —CO 2 R 20 , —C(O)N(R 20 )(R 20 ), —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , —[(W)—C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , —[(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)—C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 .

3. The method according to claim 2 , wherein R 1 is H, alkyl, hydroxyl, —C(O)R 20 , —CO 2 R 20 or —S(O) 2 R 20 .

4. The method according to claim 1 , wherein R 2 and R 3 taken together form a bond.

5. The method according to claim 1 , wherein R 4 and R 5 are each H; or R 4 and R 5 taken together form ═O or ═S.

6. The method according to claim 5 , wherein R 4 and R 5 are each H.

7. The method according to claim 1 , wherein R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are each independently H or alkyl.

8. The method according to claim 1 , wherein R 6 , R 8 , R 9 , R 10 , and R 11 are each H.

9. The method according to claim 1 , wherein X is a bond or —CH 2 —.

10. The method according to claim 9 , wherein X is —CH 2 —.

11. The method according to claim 1 , wherein Y is —O— or —N(R 24 )—.

12. The method according to claim 11 , wherein Y is —N(R 24 )—.

13. The method according to claim 1 , wherein -T 1 -T 2 -T 3 - is A-B—Y, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is NR 24 .

14. The method according to claim 1 , wherein -T 1 -T 2 -T 3 - is B—Y-A, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is O; or -T 1 -T 2 -T 3 - is Y—B-A, A is N, B is CR 23 and Y is S.

15. The method according to claim 1 , wherein R 24 is H, alkyl, or —S(O) 2 R 20 .

16. The method according to claim 1 , wherein the compound of Formula 1a is a compound of the Formula 6a:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 1 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, —SR 20 , —OR 20 , —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , —[(W)C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , —[(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 ;

R 22 independently for each occurrence is H, halide, ester, amide, or nitrile;

p is 0, 1, 2, 3, 4, 5, or 6;

q is 0, 1, 2, 3, 4, 5, or 6;

R independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl;

-T 1 -T 2 -T 3 - is Y—B-A, B—Y-A, or A-B—Y;

each of A and B independently is N, S or C(R 23 );

W is a diradical;

X is a bond or —C(R 22 ) 2 —;

Y is —O—, —S—, or —N(R 24 )—;

and each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, whether alone or part of another group, is optionally substituted.

17. The method according to claim 16 , wherein R 1 is H, alkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, —OR 20 , —C(O)R 20 , —CO 2 R 20 , —C(O)N(R 20 )(R 20 ), —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , —[(W)—C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , —[(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)—C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 .

18. The method according to claim 17 , wherein R 1 is H, alkyl, hydroxyl, —C(O)R 20 , —CO 2 R 20 or —S(O) 2 R 20 .

19. The method according to claim 16 , wherein R 4 and R 3 are each H.

20. The method according to claim 16 , wherein X is a bond or —CH 2 —.

21. The method according to claim 20 , wherein X is —CH 2 —.

22. The method according to claim 16 , wherein Y is —O— or —N(R 24 )—.

23. The method according to claim 22 , wherein Y is —N(R 21 )—.

24. The method according to claim 16 , wherein -T 1 -T 2 -T 3 - is A-B—Y, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is NR 24 .

25. The method according to claim 16 , wherein -T 1 -T 2 -T 3 - is B—Y-A, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is O; or -T 1 -T 2 -T 3 - is Y—B-A, A is N, B is CR 23 and Y is S.

26. The method according to claim 16 , wherein R 24 is H, alkyl, or —S(O) 2 R 20 .

27. The method according to claim 1 , wherein the compound of Formula 1b is a compound of the Formula 11b:

or a tautomer or pharmaceutically acceptable salt thereof,

wherein:

R 1 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, —SR 20 , —OR 20 , —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , [(W)—C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , —[(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)—C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 ;

R 22 independently for each occurrence is H, halide, ester, amide, or nitrile;

R 23 independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloalkyl, halide, nitro, nitrile, ═O, —SR 20 , —OR 20 ) N(R 20 )(R 20 ), —C(O)R 20 , —CO 2 R 20 , —OC(O)R 20 , —C(O)N(R 20 )(R 20 ), —N(R 20 )C(O)R 20 , —N(R 20 )C(O)N(R 20 )(R 20 ), —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —N(R 20 )S(O) 2 R 20 , or —[C(R) 2 ] p —R 21 ;

p is 0, 1, 2, 3, 4, 5, or 6;

q is 0, 1, 2, 3, 4, 5, or 6;

R independently for each occurrence is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl;

-T 1 -T 2 -T 3 - is Y—B-A, B—Y-A, or A-B—Y;

each of A and B independently is N, S or C(R 23 );

W is a diradical;

X is a bond or —C(R 22 ) 2 —;

Y is —O—, —S—, or —N(R 24 )—;

and each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, whether alone or part of another group, is optionally substituted.

28. The method according to claim 27 , wherein R 1 is H, alkyl, hydroxyl, aralkyl, heteroaryl, heteroaralkyl, —OR 20 , —C(O)R 20 , —CO 2 R 20 , —C(O)N(R 20 )(R 20 ), —S(O) 2 R 20 , —S(O) 2 N(R 20 )(R 20 ), —[(W)—C(O)] p R 20 , —[(W)—C(O)O] p R 20 , —[(W)—OC(O)] p R 20 , [(W)—SO 2 ] p R 20 , —[(W)—N(R 20 )SO 2 ] p R 20 , —[(W)—C(O)N(R 20 )] p R 20 , —[(W)—O] p R 20 , —[(W)—N(R 20 )] p R 20 , or —[(W)—S] p R 20 .

29. The method according to claim 28 , wherein R 1 is H, alkyl, hydroxyl, —C(O)R 20 , —CO 2 R 20 or —S(O) 2 R 20 .

30. The method according to claim 27 , wherein R 4 and R 5 are each H.

31. The method according to claim 27 , wherein X is a bond or —CH 2 —.

32. The method according to claim 31 , wherein X is —CH 2 —.

33. The method according to claim 27 , wherein Y is —O— or —N(R 24 )—.

34. The method according to claim 33 , wherein Y is —N(R 24 )—.

35. The method according to claim 27 , wherein -T 1 -T 2 -T 3 - is A-B—Y, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is NR 24 .

36. The method according to claim 27 , wherein -T 1 -T 2 -T 3 - is B—Y-A, A is CR 23 , B is N and Y is NR 24 ; or -T 1 -T 2 -T 3 - is B—Y-A, A is N, B is CR 23 and Y is O; or -T 1 -T 2 -T 3 - is Y—B-A, A is N, B is CR 23 and Y is S.

37. The method according to claim 27 , wherein R 24 is H, alkyl, or —S(O) 2 R 20 .

38. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:

or a tautomer or a pharmaceutically acceptable salt thereof;

39. The method according to claim 1 , wherein the cancer is basal cell carcinoma, pancreatic cancer, prostate cancer, osteogenic sarcoma, chondrosarcoma, non-Hodgkin's type lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, gastric cancer, esophageal cancer, multiple myeloma, lung cancer, glioma, breast cancer, hepatocellular cancer, ovarian cancer, colon cancer or medulloblastoma.

40. The method according to claim 1 , wherein the cancer is pancreatic cancer.

41. The method according to claim 1 , wherein the cancer is chondrosarcoma.

42. The method according to claim 1 , wherein the cancer is lung cancer.

43. The method according to claim 42 , wherein the lung cancer is small cell lung cancer.

44. The method according to claim 1 , wherein the cancer is basal cell carcinoma.

45. The method according to claim 1 , wherein the cancer is medulloblastoma.

46. The method according to claim 1 , wherein the cancer is acute lymphocytic leukemia.

47. The method according to claim 1 , wherein the cancer is chronic lymphocytic leukemia.

48. The method according to claim 1 , wherein the cancer is ovarian cancer.

49. The method according to claim 1 , wherein the cancer is osteogenic sarcoma.

50. The method according to claim 1 , wherein the cancer is chronic myeloid leukemia.

51. The method according to claim 1 , wherein the compound is used in combination with one or more chemotherapeutic or other anti-cancer agent.

52. The method according to claim 51 , wherein the other anti-cancer agent is radiation.

53. The method according to claim 1 , wherein the compound is administered locally to a tumor.

54. The method according to claim 1 , wherein the compound is administered systemically.

55. The method according to claim 1 , wherein the mode of administration of said compound is inhalation, oral, intravenous, sublingual, ocular, transdermal, rectal, vaginal, topical, intramuscular, intraperitoneal, epidural, subcutaneous, buccal, or nasal.

56. The method according to claim 55 , wherein the mode of administration is oral, intravenous, or topical.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2020

From: INFINITY PHARMACEUTICALS, INC.

To: ROYALTY SECURITY, LLC

Reel/Frame 051519/0511 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2009

From: CASTRO, ALFREDO C.; GROGAN, MICHAEL J.; TREMBLAY, MARTIN R.

To: INFINITY DISCOVERY, INC.

Reel/Frame 023593/0423 →

Continuity (3)

Continuation 12044817 · Mar 7, 2008

Provisional Application 60893595 · Mar 7, 2007

Related Publication 20100144775A1 · Jun 10, 2010